XML 29 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Net Income (Loss) Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
 9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

13. Net Income (Loss) Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net income (loss) per share attributable to our common shareholders for the three and nine months ended September 30, 2025 and 2024, respectively (in thousands, except share and per share amounts):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Net income (loss) attributable to Adaptive Biotechnologies Corporation

 

$

9,546

 

 

$

(32,071

)

 

$

(45,920

)

 

$

(125,800

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding - basic

 

 

152,432,307

 

 

 

147,516,398

 

 

 

151,248,398

 

 

 

146,908,234

 

Incremental shares attributable to share-based compensation plans

 

 

10,729,800

 

 

 

—

 

 

 

—

 

 

 

—

 

Weighted-average shares outstanding - diluted

 

 

163,162,107

 

 

 

147,516,398

 

 

 

151,248,398

 

 

 

146,908,234

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

0.06

 

 

$

(0.22

)

 

$

(0.30

)

 

$

(0.86

)

The number of weighted-average common stock equivalents excluded from the calculation of diluted net income (loss) per share attributable to our common shareholders because of their anti-dilutive effect were 5.9 million and 26.9 million for the three months ended September 30, 2025 and 2024, respectively, and 28.0 million and 27.0 million for the nine months ended September 30, 2025 and 2024, respectively. These common stock equivalents are comprised of shares that may be issued under our stock option, restricted stock, market-based restricted stock and performance-based restricted stock programs.